Home›Trial›NCT07095465
🔬NCT07095465Phase 3ENROLLING BY INVITATION

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Study Summary

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Conditions
Lewy Body Dementia Psychosis
Interventions / Drugs
ACP-204
View on ClinicalTrials.gov ↗
Sponsor
ACAD
ACADIA Pharmaceuticals
Neuroscience
D50/100
Study Details
Enrollment126 participants
Primary Completion—
Lead SponsorACADIA Pharmaceuticals Inc.
Data Retrieved2026-04-11 02:52:05.277027+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.